Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 355-361 , May 2009

In vivo examination of 188Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer

  • Kuo-Ting Chen

      Affiliations

    • Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan
    • ,
  • Te-Wei Lee

      Affiliations

    • Institute of Nuclear Energy Research, Longtan 32546, Taiwan
    • ,
  • Jem-Mau Lo

      Affiliations

    • Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan
    • Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 30013, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan. Tel.: +886 3 5727308; fax: +886 3 5718649.

Received 7 November 2008 ,Revised 5 January 2009 ,Accepted 12 January 2009.

References 

  1. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  2. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232:123–138
  3. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756–760
  4. Plosker GL, Keam SJ. Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs. 2006;66:449–475
  5. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701–706
  6. Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, et al. Preclinical characterization of 111In-DTPA-trastuzumab. Br J Pharmacol. 2004;143:99–106
  7. Chen WJ, Yen CL, Lo ST, Chen KT, Lo JM. Direct 99mTc labeling of Herceptin (trastuzumab) by 99mTc tricarbonyl ion. Appl Radiat Isot. 2008;66:340–345
  8. Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nucl Med Biol. 2005;32:51–58
  9. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5:292–302
  10. Schibli R, Schwarzbach R, Alberto R, Ortner K, Schmalle H, Dumas C, et al. Steps toward high specific activity labeling of biomolecules for therapeutic application: preparation of precursor [188Re(H2O)3(CO)3]+ and synthesis of tailor-made bifunctional ligand systems. Bioconjug Chem. 2002;13:750–756
  11. Budman DR, Tai J, Calabra A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer lines in vitro. Breast Cancer Res Treat. 2007;104:93–101
  12. Lin WY, Tsai SC, Hsieh BT, Lee TW, Ting G, Wang SJ. Evaluation of three rhenium-188 candidates for intravascular radiation therapy with liquid-filled balloons to prevent restenosis. J Nucl Cardiol. 2000;7:37–42
  13. Li G, Wang Y, Huang K, Zhang H, Peng W, Zhang C. The experimental study on the radioimmunotherapy of the nasopharyngeal carcinoma overexpressing HER2/neu in nude mice model with intratumoral injection of 188Re-herceptin. Nucl Med Biol. 2005;32:59–65

PII: S0969-8051(09)00009-2

doi: 10.1016/j.nucmedbio.2009.01.006

Nuclear Medicine and Biology
Volume 36, Issue 4 , Pages 355-361 , May 2009

Article Tools

* Image Usage & Resolution